Inventiva in Numbers
Innovative Clinical Programmes
People in our Scientific Team
A Library of
Welcome to Inventiva Pharma
We are a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of patients with significant unmet medical need in the areas of fibrosis, lysosomal storage disorders and oncology.
We have built a pipeline backed by a discovery engine with an extensive library of proprietary molecules, a wholly-owned research and development facility and a team with significant expertise and deep experience in the development of compounds that target nuclear receptors, transcription factors and epigenetic modulation.
By leveraging these assets and expertise, we are advancing two clinical candidates, as well as a deep pipeline of earlier stage programs.About Inventiva
H1 2021 financial results
Share Information€11.8 -1.17%
Last update: May 14, 2021 at 09:45 CET
Previous close: €11.94
Day High: €11.98
Day Low: €11.8
Non-Alcoholic Steatohepatitis (NASH)
Non-alcoholic steatohepatitis is a severe liver disease which affects 6-8% of adults in western industrialised nations and is on the rise around the globe.
Inventiva is developing lanifibranor for the treatment of NASH to address all the key features of this disease: inflammation, steatosis, ballooning, and more importantly fibrosis.
Lanifibranor completed a phase IIb study. After only 6 months of treatment, lanifibranor achieved statistically significance in both regulatory endpoints required by FDA and EMA: resolution of NASH without worsening of fibrosis and reduction in fibrosis without worsening of NASH. These results, in addition to an excellent safety profile, clearly differentiate lanifibranor from any other treatment in development for NASH. For more details of the headline results see the results presentation.
MPS is a group of rare genetic disorders characterized by an excessive accumulation of large sugar chains, known as glycosaminoglycans, or GAGs, in cells.
Inventiva is developing odiparcil, an orally-available small molecule designed to modify how GAGs are synthesized.
In the recently completed iMProveS phase IIa study, odiparcil confirmed its favourable safety profile and demonstrated efficacy in adult MPS VI patients, especially in tissues types not reached by standard of care.
Phase IIb trial in NASH, enrollment completed
Phase IIa in adult MPSVI patients, completed
50 Rue de Dijon
21121 Daix, France
Email : firstname.lastname@example.org
Call : +33 (0)3 80 44 75 00